- Home
- AGEN vs AIRG Comparison
AGEN vs AIRG Comparison
Compare AGEN & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- AIRG
- Stock Information
- Founded
- AGEN 1994
- AIRG 1995
- Country
- AGEN United States
- AIRG United States
- Employees
- AGEN N/A
- AIRG N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- AIRG Radio And Television Broadcasting And Communications Equipment
- Sector
- AGEN Health Care
- AIRG Technology
- Exchange
- AGEN Nasdaq
- AIRG Nasdaq
- Market Cap
- AGEN 96.2M
- AIRG 107.7M
- IPO Year
- AGEN 2000
- AIRG 2016
- Fundamental
- Price
- AGEN $2.86
- AIRG $8.58
- Analyst Decision
- AGEN Buy
- AIRG Strong Buy
- Analyst Count
- AGEN 3
- AIRG 2
- Target Price
- AGEN $9.33
- AIRG $11.75
- AVG Volume (30 Days)
- AGEN 576.6K
- AIRG 38.1K
- Earning Date
- AGEN 11-12-2024
- AIRG 11-12-2024
- Dividend Yield
- AGEN N/A
- AIRG N/A
- EPS Growth
- AGEN N/A
- AIRG N/A
- EPS
- AGEN N/A
- AIRG N/A
- Revenue
- AGEN $160,427,000.00
- AIRG $55,586,000.00
- Revenue This Year
- AGEN N/A
- AIRG $13.95
- Revenue Next Year
- AGEN $0.04
- AIRG $18.52
- P/E Ratio
- AGEN N/A
- AIRG N/A
- Revenue Growth
- AGEN 59.00
- AIRG N/A
- 52 Week Low
- AGEN $2.50
- AIRG $2.25
- 52 Week High
- AGEN $19.69
- AIRG $10.34
- Technical
- Relative Strength Index (RSI)
- AGEN 28.17
- AIRG 42.00
- Support Level
- AGEN $2.50
- AIRG $8.82
- Resistance Level
- AGEN $2.89
- AIRG $10.00
- Average True Range (ATR)
- AGEN 0.29
- AIRG 0.50
- MACD
- AGEN -0.07
- AIRG -0.16
- Stochastic Oscillator
- AGEN 18.75
- AIRG 15.79
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.